News | December 30, 2023
Venus Remedies secures marketing approval from Israel, Colombia for two oncology drugs
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Receives registration of Valganciclovir powder for oral solution in Germany
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Subscribe To Our Newsletter & Stay Updated
